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There is a major shortage of organs in the United States resulting in thousands of deaths 
per year. One main approach for responding to this crisis has been to consider expanding criteria 
for donation to increase the pool of available organs. The HIV Organ Policy Equity Act (HOPE 
Act) legalized HIV+ to HIV+ organ transplants, allowing HIV+ organs to be used in transplants 
in the U.S. for the first time. But even with this policy there is still untapped potential in 
considering HIV+ organs for transplant. Under current law HIV+ living donors cannot donate to 
HIV- recipients even if no alternative organ is available. Similarly, HIV- potential organ recipients 
are forbidden from accepting an HIV+ organ even if the organ would otherwise be discarded or 
would be given to a person on the waitlist who is in less desperate need of it. In the early years of 
the HIV pandemic these prohibitions were logical as HIV was a deadly disease with no effective 
treatment. Yet today this is no longer the case and people living with HIV can live long fulfilling 
lives. As such, legalizing HIV+ to HIV- organ transplantation in the United States has great 
potential to save lives and improve quality of life. This essay will explore the risks and benefits of 
this procedure and argue that it is prudent to legalize HIV+ to HIV- transplantation.  
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This paper will argue in favor of legalizing HIV+ to HIV- organ transplantation in the 
United States. The paper will be divided into the following sections: background information 
including an explanation of the HOPE Act and a HIV+ to HIV- transplant case study; an 
examination of the current organ allocation systems in the US; an analysis of whether HIV+ to 
HIV- organ transplantation conforms to established biomedical ethical principles; an evaluation of 
different allocation schemes incorporating HIV+ to HIV- donation; a section explaining how new 




Over 100,000 people in the United States are currently waiting for an organ transplant 
(“Facts and myths about transplant,” n.d.). On average, the shortage of organs results in 20 deaths 
a day, with the majority of those deaths—about 13 a day—from those waiting for a kidney 
transplant (“Facts and myths about transplant,” n.d.; “Organ donation and transplantation 
statistics,” n.d.). Working to solve this problem demands creativity and innovation. Allowing 
HIV+ to HIV- organ transplantation has the potential to increase the pool of organs available, save 
lives, and improve quality of life for transplant recipients. Requiring that the transplants be 
performed in a research context—as was also a requirement of legalizing HIV+ to HIV+ 
transplantation—will provide valuable information about the comprehensive impacts of the 
procedure (National Institute of Allergy and Infectious Diseases, 2019). However, this essay will 
show that even now, in the absence of this information, the benefits of allowing HIV+ to HIV- 
transplantation likely outweigh the costs. 
2.2 The HOPE Act 
The HIV Organ Policy Equity Act (or HOPE Act) was implemented in 2015 (“Hope Act,” 
n.d.). This act legalized HIV+ to HIV+ organ transplantation conducted for research purposes 
(“Hope Act,” n.d.). Before passage of the Act, researchers had estimated that legalizing HIV+ to 
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HIV+ organ transplantation would increase the total pool of donor organs available by ~350-650 
per year (Boyarsky et al., 2011; Richterman et al., 2015). Additionally, once the Act was passed 
another benefit became apparent in that due to the false-positive rates of tests used to screen for 
HIV an additional 50-100 donors who were actually HIV- but labeled as HIV+ would be able to 
donate—as before the passage of the HOPE Act their organs would have been discarded due to 
concerns about HIV transmission (Boyarsky et al., 2019; Durand et al., 2018). In addition to 
providing lifesaving organ transplants to HIV+ organ recipients this act benefits HIV- potential 
recipients as well since increasing the number of transplants lowers the number of people on the 
waitlist (Boyarsky et al., 2019). However, despite all of these advancements made under the HOPE 
Act the next section will show that only allowing HIV+ to HIV+ transplantation will not save 
every life that could be saved by receiving an HIV+ organ. 
2.3 Intentional HIV+ to HIV- Transplant Performed in South Africa in 2017 
South Africa is similar to the United States in that there is a major shortage of organs 
available for transplant (Etheredge et al., 2019). The countries also resemble each other in that 
both have been able to largely transition from the initial state of the HIV pandemic where infection 
meant death to one where HIV infection can be managed and becomes a chronic illness that one 
can live with for many years (Etheredge et al., 2019). For the Etheredge et al. team these two 
considerations meant that there was increased pressure to reconsider policies preventing persons 
living with HIV to act as donors for HIV- organ recipients (Etheredge et al., 2019). It seemed 
increasingly doubtful that preventing the possible harm of HIV infection was worth the 
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consequences of failing to receive a life-saving organ transplant. This was particularly true in one 
case involving an HIV+ mother and her HIV- daughter who was awaiting liver transplant:  
“As the child’s health deteriorated, it became clear that the 
living donor option, with the child’s HIV-positive mother as the 
donor, was our only hope of saving the child’s live. Due to SA’s 
[South Africa’s] solid organ shortage, it was highly likely that the 
child would die before a deceased donor liver could be procured. 
The HIV-positive living donor option was only pursued after all 
other willing family members had been found ineligible for living 
donation. The child remained on our deceased donor waiting list 
until transplant, and at the time of transplant had been listed for 181 
days, almost four times the average for our programme” (Etheredge 
et al., 2019) 
 
The team had decided to proceed with the transplant expecting the child to become infected 
with HIV reasoning that the consequences of such an infection would be outweighed by the 
benefits the organ transplant provided (Etheredge et al., 2019). At the time the article detailing the 
procedure was published—almost two years after the transplant had taken place—both the mother 
and the child were in good health and the child seemed to have greatly benefitted from the 
procedure (Etheredge et al., 2019). 
2.4 Beauchamp and Childress Principles of Biomedical Ethics 
In biomedical ethics there are four main principles that are often used to determine whether 
a medical procedure or system is morally acceptable. These principles, as described by Tom L. 
Beauchamp & James F. Childress are: 
“(1) respect for autonomy (a norm of respecting and 
supporting autonomous decisions), (2) nonmaleficence (a norm 
avoiding the causation of harm), (3) beneficence (a group of norms 
pertaining to relieving lessening, or preventing harm and providing 
benefits and balancing benefits against risks and costs), and (4) 
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justice (a cluster of norms for fairly distributing benefits, risks, and 
costs)” (Beauchamp & Childress, 2019, p. 13) 
 
These four principles must be balanced against each other with no one principle 
outweighing all the others. In some situations, the balancing is obvious: “If in a particular case a 
heath care provider inflicts a minor injury—swelling from a needlestick, say—but simultaneously 
provides a major benefit such as saving the patient’s life, it is justified to conclude that the 
obligation of beneficence takes priority over the obligation of nonmaleficence in this case” 
(Beauchamp & Childress, 2019, p. 156). However, in many situations, such as in the case of organ 
donation, it is not always apparent what the best approach is. Yet, the principle of balancing still 
plays a role. For example, “Rationing schemes that either minimize or altogether exclude 
considerations of medical utility are indefensible, but judgments of medical utility are not always 
sufficient by themselves” (Beauchamp & Childress, 2019, p. 310). Instead, a combination of 
medical utility and other factors is a more appropriate basis for allocation of scarce resources as 
“It is generally legitimate to invoke medical utility followed by the use of chance or queuing for 
scarce resources when medical utility is roughly equal for eligible patients” (Beauchamp & 
Childress, 2019, p. 312). There are many different ways to construct such a system prioritizing 
medical utility while considering other values but in many cases what is theoretically possible 
might not be practical to implement. As such, the next section will investigate how the already-
established organ allocation system in the United States is constructed and if/how it balances the 
principles of biomedical ethics elucidated by Beauchamp & Childress.  
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3.0 Examination of UNOS/OPTN Guidelines1 
Before looking at whether HIV+ to HIV- transplantation should be considered, it would be 
prudent to review the guidelines that are already in place for organ transplantation in the United 
States—both to understand the values apparent in the current system and to gain a greater 
appreciation of the general structure that a newly approved procedure would have to feasibly fit 
into. The following is a general summary of how deceased donor organs are allocated depending 
on organ type based on guidelines put forth by the Organ Procurement and Transplantation 
Network (OPTN) under the United Network for Organ Sharing (UNOS). In an effort to be brief, 
only three organ types will be described—heart, liver, and kidney. Liver and kidney were picked 
because under current legislation these are the only two organs that HIV+ to HIV+ transplantation 
is focused on (National Institutes of Health, n.d.). Heart was included because the allocation 
system for this type of organ is a good middle ground between the very simple liver allocation 
system and the incredibly complex kidney one. The following descriptions are general 
summaries—there are exceptions to the rules but the aim of this section is not to give every detail 
of the allocation systems but rather to identify trends and themes. 
 
1 All information in this section unless otherwise indicated is from this source: (Organ Procurement and 
Transplantation Network Policies, 2020) 
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3.1 Allocation of Livers 
We will begin by looking at the most straightforward allocation system—the one for livers. 
For this system there are only two main categories for adult potential recipients: those who have a 
life expectancy of 7 days without a transplant (status 1A) and everyone else. Pediatric candidates 
have a similar classification with the addition of a middle category. For the classification (a section 
of which is provided below) candidates with status 1A (both adult and pediatric) and geographic 
proximity to the donor get priority, then the middle category pediatric candidates, then individual 
MELD/PELD (Model for End-Stage Liver Disease/Pediatric End-Stage Liver Disease) scores 
decreasing in severity alternating between a small geographic area2 and a medium sized-
geographic area3, before opening up the geographic area to the entire nation and returning to the 
candidates with more severe cases. So, for example, a person with a MELD/PELD score of 35 
within the smallest geographic area has a higher priority than a person with a MELD/PELD score 
of 15 within the middle geographic area (i.e. classification 13 vs. classification 15). But, the 
candidate with a MELD/PELD score of 15 within the same region as the donor’s Organ 
Procurement Office (OPO) has a higher priority than a person with status 1A who is only in the 
same nation. These MELD/PELD scores combine several lab tests for substance concentrations 





2 Formally, this is the donor’s Organ Procurement Office’s donation service area 
3 One of 11 established regions that subdivides the entire US 
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Table 1: Allocation of Liver Sample Table 
Classification Geographic region Criteria 
1 medium Status 1A 
2 medium Status 1B 
3 small MELD/PELD of 40 
4 medium MELD/PELD of 40 
5 small MELD/PELD of 39 
6 medium MELD/PELD of 39 
… … … 
13 small MELD/PELD of 35 
14 medium MELD/PELD of 35 
15 small MELD/PELD > 15 
16 medium MELD/PELD > 15 
17 nation Status 1A 
18 nation Status 1B 
… … … 
 
This system seems pretty easy to understand—it seeks to maximize the number of lives 
saved and secondarily to maximize the number of life-years saved. People with the most urgent 
need of transplant are given priority whether they are an adult or a child. The list then shifts to a 
special pediatric category—prioritizing those who are likely to live with the organ longer than 
older candidates. Geographic region is the strangest factor and the hardest one to explain. 
Historically, geographic proximity to the donor was important because organs would become less 
viable the longer they were outside a human body—geography had to be prioritized otherwise 
many organs wouldn’t be usable (Institute of Medicine, 1999). With current technology, time 
outside the body is less of an issue—though still relevant to a certain extent (Institute of Medicine, 
1999). There have been many calls to substantially revise the role of geography in the allocation 
system, and this remains a contentious issue (Snyder et al., 2018; Spaggiari et al., 2019).  
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3.2 Allocation of Hearts 
In the allocation of hearts, an adult candidate can be assigned a status from 1-6, with status 
1 indicating the most severe conditions and 6 the least. A pediatric candidate can be assigned status 
1A, 1B, or 2, also depending on severity with 1A representing the highest level of severity. Adult 
donor allocation classifications prioritize the highest (most severe) classes and the smallest 
geographical regions4, with the list beginning with the smallest geographical areas and moving 
down a few statuses before returning to the higher statuses but at a greater distance. For candidates 
that have the same status and region, the secondary blood type match immediately follows the 
primary blood type on the list. The pediatric allocation classifications are similar to the adult ones 
but prioritize the pediatric status over the comparable adult: pediatric 1A then adult 1 then adult 2 
then pediatric 1B. So, for example, a person with Pediatric Status 1A who is a secondary blood 
type match with the donor and within 1000 miles of them has a higher status than someone with 
Adult Status 2 and a primary blood type match and within 1000 miles (classification 8 vs. 9). So, 
as we can see, there are a variety of factors that are important in the allocation of hearts. Severity 
of condition, geographical region, pediatric status, and blood type are all taken into consideration 






4 Regions for hearts are defined by proximity to donor—for example within 500 miles of the donor 
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Table 2: Allocation of Hearts Sample Table 
Classification Geographic Region Status 
1 500 miles Adult Status 1/Pediatric 
Status 1A, primary blood type 
match with donor 
2 500 miles Adult Status 1/Pediatric 
Status 1A, secondary blood 
type match with donor 
3 500 miles Adult Status 2, primary blood 
type match with donor 
4 500 miles Adult Status 2, secondary 
blood type match with donor 
… … … 
8 1000 miles Adult Status 1/Pediatric 
Status 1A, secondary blood 
type match with donor 
9 1000 miles Adult Status 2, primary blood 
type match with donor 
10 1000 miles Adult Status 2, secondary 
blood type match with donor 
11 250 miles Adult Status 4, primary blood 
type match with donor 
12 250 miles Adult Status 4, secondary 
blood type match with donor 
… … … 
 
But why are all these factors so important? Severity of condition is pretty obvious just like 
it was with livers—it prioritizes the people who need the organ most so that the allocation is set 
up to save as many lives as possible. Pediatric status is similarly easy to explain: in general, we 
want organs to go to children who have not yet had the opportunity to live for a substantial period 
of time. Additionally, we want organs to be used for as long as possible, and a 16-year-old is more 
likely to live several more decades with a transplant than an 80-year-old or even a 50-year-old. It 
is notable that Adult Status 2 is prioritized over Pediatric Status 1B, since this means that severity 
of condition is balanced with pediatric status instead of all organs first being offered to pediatric 
candidates. Blood type at first seems an odd factor to consider but becomes more obvious when 
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one considers that graft loss is a serious concern with organ transplant. If we wanted to maximize 
the number of years that a person lives with an organ we would want to make sure that the 
particular organ was as compatible as possible with the potential recipient, and blood type would 
be a significant biological indication of compatibility. So, for potential recipients that are otherwise 
equal—same status and distance from donor—it makes sense to prioritize the potential recipients 
who are more likely to be able to live with the organ for a longer period of time, i.e. those with 
primary blood type matches are prioritized over those with secondary blood type matches. Finally, 
once again we see that geographic proximity to the donor remains a relevant factor. 
3.3 Allocation of Kidneys 
Let’s now turn to another, more complicated, organ type—the kidney. Like with hearts 
kidney allocation depends on many factors. However, unlike hearts, these factors are associated 
with several scores (often acronyms) that determine allocation. The first score to be aware of is 
the kidney donor profile index (KDPI) score, which as the name suggests is a score associated with 
the donor, not the recipient. This score represents the percentage of kidneys that are expected to 
be of better quality than the kidney the score is assigned to. So, for example, a kidney with a KDPI 
of 90% is expected to be of lower quality than 90% of kidneys recovered for donation. Several 
factors determine KDPI including but not limited to age, creatinine concentration5, weight, and 
HCV status—all given specific weights in a formula that outputs a number that can be turned into 
the KDPI score. Different KDPI ranges are given different allocation lists for recipients, with the 
 
5 A measure of how well the donor kidneys are able to filter blood 
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biggest difference between the lists being that as KDPI increases several criteria on the list are 
combined. For example, there are 69 different allocation categories a potential recipient could be 
placed in for a kidney with a KDPI score of 0-20%, but only 37 for a kidney with a KDPI >85%. 
Despite this difference, the allocation categories tend to follow the same general pattern. Potential 
recipients with the highest CPRA (Calculated Panel Reactive Antibodies—a measure of the 
percent of donors on the waiting list that are incompatible with that particular potential recipient) 
are given organs first, starting with the smallest geographical region6 and then working outward. 
Once 100%-98% CPRA candidates have been exhausted, the priority is given to candidates 
younger than 18 (except for the >85% KDPI list, which does not mention pediatric candidates) 
and candidates with a top 20% EPTS (Estimated Post Transplant Survival) score are given 
priority—a score which is calculated based on candidate age, time on dialysis, history of organ 
transplant, and diabetes diagnosis. Candidates with CPRAs of 21%-79% soon follow, then the 
geographic area is broadened. In general, candidates with zero antigen mismatches with the donor 
organ are given priority over similar cases without. So, for example, a candidate with a CPRA of 
100%, a permissible or identical blood type, within the small geographic region, and with a 0-
ABDR mismatch is given priority over a candidate that meets all the same criteria except the 0-






6 The geographic regions are the same as for livers (OPO DSA and OPO Region) 
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Table 3: Allocation of Kidneys Sample Table (KDPI>85%) 
Classification Geographic Area Criteria Donor Blood Type 
1 small 0-ABDR mismatch, 
CPRA: 100%, blood 
type permissible or 
identical 
Any 
2 small CPRA: 100%, blood 
type permissible or 
identical 
Any 
3 medium 0-ABDR mismatch, 
CPRA: 100%, blood 
type permissible or 
identical 
Any 
4 medium CPRA: 100%, blood 
type permissible or 
identical 
Any 
… … … … 













16 medium 0-ABDR mismatch, 
21%<CPRA<79%, 
blood type identical 
Any 
17 nation 0-ABDR mismatch, 
21%<CPRA<79%, 
blood type identical 
Any 
18 small 0-ABDR mismatch, 
blood type B 
O 




… … … … 
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Within each classification, a points system is used to give priority. This points system 
incorporates a variety of factors such as waiting time, CPRA score, and whether the candidate is a 
prior living donor. 
Table 4: Kidney Points Sample Table 
Criteria Points 
Waiting time 1/365 points for each day 
Aged 0-10 at time of match and a 0-ABDR 
mismatch with the donor 
4 points 
Aged 11-17 at time of match and a 0-ABDR 
mismatch with the donor 
3 points 
Prior living donor 4 points 
CPRA at least 20% Increases according to CPRA score, ex. 20-
29%=0.08 points, 60-69%=0.81 points, 80-
84%=2.46 points, 96%=12.17 points 
 
There’s a lot that goes into the kidney allocation system but we can still extract out some 
general values from how it is set up. Different lists for different KDPIs indicate a desire to treat 
allocation of preferred organs differently from those deemed less favored. The fact that the 
allocation categories are combined as KDPI increases suggests that each of the factors that go into 
creating the different allocation categories matter less in comparison to each other when the organ 
is determined to be of lower quality according to KDPI score. Prioritizing recipients with higher 
CPRA scores points to an attempt to maximize equity among potential recipients—those with the 
highest CPRA scores have the lowest chance of finding a match, so if one comes up it would likely 
be the only one they would ever get whereas candidates with lower CPRA scores can be relatively 
certain that another match will come along in time. As such, this principle also works to maximize 
the number of lives saved, as people who are compatible with many different organ types only get 
organ offers that are not compatible with those with many restrictions. As far as zero antigen 
mismatch is concerned, this is similar to matching blood type in heart transplants—minimizing 
graft loss when possible. Once again we see that geographic region plays a role in allocation. The 
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points system serves to balance several factors against each other. But most of these factors seem 
to have an underlying value of fairness—those who have been on the waitlist longer are given 
priority along with those who have previously donated an organ and now need one. The 
prioritization of prior living donors also works to incentivize living donation, increasing the pool 
of available organs overall. 
 In general, the reason the kidney allocation system is more complicated than heart or liver 
is that patients with nonfunctional kidneys can live for considerably longer periods of time than 
those with a nonfunctional heart or liver. This means that there are considerably more people on 
the wait list for kidneys in general and more people on the wait list who are not at immediate risk 
of death—so other factors besides immediate need become relevant. 
3.4 Summary 
Even though there are many differences in the allocation systems it seems there are also 
some repeating themes and underlying values. Prioritizing those who need the organ most seems 
to be a consideration that runs through all three of the allocation systems we have looked at—and 
by extension saving the most lives seems to be an important goal for the allocation system. This 
goal is balanced with a desire to prioritize pediatric candidates and other candidates who would be 
likely to live with the transplanted organ for the longest period of time. Fairness also seems to be 
an important secondary consideration once all candidates who are in desperate need of an organ 
have been considered. Factors like prioritizing prior living donors serve to incentivize an increase 
in the pool of organs offered, thereby also saving as many lives as possible.  
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4.0 Application of Values to Proposed HIV+ to HIV- Transplantation Procedure 
Because of the myriad of factors that go into developing health care policy determining 
whether a particular principle—or in this case procedure—can be practically executed is no simple 
task. We have seen from the analysis of OPTN/UNOS’s guidelines that no one factor outweighs 
all the others, and that many different considerations are relevant to this particular discussion. As 
such, it is prudent to consider how the proposed HIV+ to HIV- transplant procedure does or does 
not conform with the identified values of organ donation in the United States. This is what I will 
endeavor to do in the following sections. 
4.1 Considerations of Beneficence and Nonmaleficence  
In the previous section it was determined that saving the most lives was an important goal 
for OPTN/UNOS. On this consideration alone it seems that the proposed procedure would be likely 
to align with this goal. In general, “If we wanted to maximize transplant, we would want a system 
that accepts organs that are known in advance to be somewhat suboptimal” (Veatch, 2000, p. 240). 
This makes sense, as demand for organs currently outstrips supply, and “[t]he median waiting time 
for an organ is 1-7 years and can be significantly longer for highly sensitized or difficult to match 
recipients” (Kucirka et al., 2011). Increasing the number of organs deemed transplantable should 
reduce the waiting time for an organ and thus increase transplants and reduce the number of people 
who die while on the waitlist. It is tempting to argue that since HIV+ to HIV+ transplantation is 
already allowed, that opening up transplantation to HIV+ to HIV- cases would not actually increase 
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the number of transplants—as the HIV+ organs are already deemed transplantable (albeit only in 
some cases). What this argument fails to consider is that even if a particular organ is determined 
to be of a high enough quality to be used in a transplant, it must be matched to a candidate for that 
transplant to be carried out. We have seen in the previous section that several factors impact 
whether a candidate can be matched with a donor organ—notably geography and biological 
considerations like blood type. The HIV+ population in the United States is small—about 13 per 
100,000 people—and as such, it is likely that there will be some cases where HIV+ organs are 
considered transplantable but there is no HIV+ candidate who meets the appropriate criteria to 
accept that organ for transplantation (HIV.gov, June 2020). Widening the pool of candidates to 
those who are HIV- but willing to accept an HIV+ organ would increase the likelihood that an 
HIV+ donor organ is able to be matched with a candidate. It is not a ridiculous assumption that 
there might be HIV- candidates willing to accept HIV+ organs—particularly candidates who are 
in such desperate need of an organ that rejecting the offer likely means death. Philosopher Robert 
Veatch put it the following way: 
“If death is the only alternative for someone who cannot 
obtain a negative organ, I do not see why someone would decline. 
There is no firm evidence on the incidence of transmission in such 
a situation. The risk surely should be presumed to be high. But the 
risk of dying without transplant may also be very high. Given the 
fact that people with infection are now living many years symptom 
free, I can imagine some people preferring that risk to certain, rapid 
death” (Veatch, 2000, p. 252) 
 
Veatch made this argument in 2000 and treatment for HIV has improved since then. If a 
logical argument could be put forth twenty years ago on why some patients might consider HIV+ 
to HIV- donation, it is easy to see why some might make the same argument today and decide that 
they would be better off accepting an HIV+ organ. Considerations of beneficence compel us to 
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honor the decisions that benefit people when possible. As such, the idea that lives could be saved 
as a result of this procedure should be taken very seriously. 
When considering a new procedure, it is logical to ask what the risks are. Transplant 
providers would likely be concerned that HIV+ to HIV- donation is not worth the potential risks it 
entails—HIV transmission being the main concern. “Transmission of viral infections through solid 
organ transplantation can lead to adverse outcomes for recipients, including reduced quality of life, 
graft loss, and death” (Singer et al., 2008). Indeed, nonmaleficence is another principle that 
Beauchamp and Childress emphasize balancing against other factors. The arguments put forth in 
the previous paragraph about how the new procedure could increase the number of lives saved 
become less convincing if it is the case that HIV transmission is extremely likely and leads to a 
poor quality of life—or even a reduced lifespan—after transplant. As such, the next section will 
detail what we know and can infer about HIV+ to HIV- transplantation and what a candidate who 
agrees to such a procedure can expect. 
HIV transmission risk is not only a concern for HIV+ to HIV- transplantation, but HIV+ 
to HIV+ transplantation as well. Because it is possible to be infected with more than one strain of 
HIV, “One of the main theoretical risks [of HIV+ to HIV+ transplantation] is donor-to-recipient 
HIV superinfection, defined as recipient acquisition of a distinct HIV strain from the donor” 
(Boyarsky et al., 2019). Considering that organ transplantation likely carries a higher risk of 
infection than intravenous drug use or sexual contact, there was great concern that HIV 
superinfection was extremely likely (Boyarsky et al., 2019; Muller & Barday, 2018). However, as 
of 2019, “superinfection is thought to occur rarely on ART [Antiretroviral Therapy]” which 
suggests that the process of preparing the organ for transplant as well as effective management of 
the infection through ART might be sufficient to prevent infection (Boyarsky et al., 2019). Yet, it 
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should be noted that lack of incidence of HIV superinfection through transplant does not mean that 
a HIV- person who is exposed to the virus through transplantation carries a similar reduced risk of 
infection from the donor. Superinfection is associated with an increased viral load, to the point 
where the latter is often thought of as necessary for the former. Take for example this quote from 
an article about a series of HIV+ to HIV+ transplants: “Initial concerns about transplanting HIV-
positive allografts into HIV-positive recipients in this clinic revolved around the possibility of HIV 
superinfection. However, all recipients remained virally suppressed several years after the 
transplant” (Muller & Barday, 2018). But, it could be the case that the transplant recipients were 
indeed infected with another strain of the virus, but that their current medications were able to 
suppress both strains. This problem of diagnosing HIV infection while on treatment pertains to the 
2017 South Africa case as well. Throughout their report, Etheredge et al. consistently report the 
recipient’s HIV status as indeterminate, even considering that the article was written almost two 
years after the procedure was performed (Etheredge et al., 2019). The difficulty with diagnosis for 
Muller & Barday and Etheredge et al. lies in the fact that the very tests used to diagnose HIV 
infection fail when a patient is already effectively managing the infection through ART, and the 
only way to know for certain whether the organ recipient had indeed contracted HIV would be to 
withdraw treatment and monitor—which could be life-threatening in an immunosuppressed patient 
(Etheredge et al., 2019). So, it is very likely that were HIV+ to HIV- donation to be enacted, the 
recipient of the organ would not definitively know whether they had been infected—possibly for 
the rest of their life. The psychological burden of such an experience should be taken into account 
when determining the possible risks and benefits of HIV+ to HIV- donation, and as of right now, 
those who consent to undergo the procedure should expect to become infected with the virus and 
be prepared to undergo treatment for HIV for the rest of their lives. 
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Since we have been unable to establish whether HIV transmission through organ transplant 
could be prevented, it is useful to analyze the potential consequences of becoming infected with 
the virus. “Combined antiretroviral therapy (ART) has made HIV infection a manageable chronic 
disease, allowing a near normal lifespan” (Miro et al., 2019). Regarding transplant, both graft 
survival times and patient survival times are similar between HIV+ and HIV- transplant recipients7 
(Locke et al., 2015). What is more difficult to quantify but still an important part of living with 
HIV is the stigma associated with the disease. The harm of the ongoing stigma is likely to affect 
each potential organ recipient differently, where some might consider it as an absolute 
contraindication to receiving an organ from a HIV+ donor whereas it might not matter much to 
others. As such, part of the consent process for this procedure should include a discussion of how 
HIV stigma could affect the potential recipient’s life were they to receive an organ from a HIV+ 
donor. 
What should also be considered in determining the possible consequences of HIV+ to HIV- 
transplantation is the potential that the organ recipient could infect others with the virus—in 
particular, others who might not have access to appropriate treatment for the disease. The harm 
that could be caused to others would be an acceptable reason to constrain the autonomous choices 
of the potential organ recipient (Beauchamp & Childress, 2019, p. 105). As discussed previously, 
when a person infected with HIV is effectively managing the infection with ART, transmission 
risk is thought to be extremely low8 (Boyarsky et al., 2019). This is known as “treatment as 
prevention” (HIV.gov, February 2020). So, the organ recipient has a great incentive to take the 
 
7 Notably, this is not the case when the recipient is infected with both HIV and HCV, as these patients experience 
reduced graft survival and patient survival times (Locke et al., 2015) 
8 Transmission through sex: effectively no risk; transmission through pregnancy, labor, and delivery: 1% or less; 
transmission related to drug use: still unknown but risk is likely reduced (Centers for Disease Control and Prevention, 
n.d.) 
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medication that will prevent transmission of HIV because it is also the exact medication that will 
stop the virus from attacking their own body. And, as has been established, it is unclear whether 
or not an organ transplant from a HIV+ donor to a HIV- recipient will indeed result in transmission. 
However, if we assume that transmission does occur, if the organ recipient in this case was unable 
to control the infection—either because no effective course of treatment could be found or because 
of a lack of compliance—then it is entirely possible that the recipient could infect others with HIV. 
Since this risk of transmission directly comes from the organ transplant procedure, determining 
whether this is an acceptable potential consequence of the procedure is vital. It is useful at this 
point to return to the discussion of HIV+ to HIV+ transplantation, because while the transmission 
risks are not identical, they do share some commonalities. As we have seen, even though 
uncontrollable superinfection has not in practice manifested as a common consequence of the 
procedure, at the time of legalizing HIV+ to HIV+ transplantation it was a serious concern. This 
suggests that it was considered an acceptable risk that there was the possibility that some organ 
recipients could receive organs that would directly make it so the organ recipient could transmit 
the infection from themselves to others. Regarding HIV+ to HIV- transplant, there are a lot of 
events that must take place for the infection to be transmitted—the organ recipient must be infected 
with HIV through transplant and they must fail to control the infection and they must participate 
in an activity where HIV transmission could take place. If any one of these three events fails to 
occur, transmission will similarly not occur. What is likely to occur as a result of HIV+ to HIV- 
transplantation is that the organ recipient will receive an organ that they desperately need and will 
likely extend their life and improve its quality—even if they do become infected with HIV. Thus, 
the potential risk of infecting others with HIV seems outweighed by the likely benefits of the organ 
transplant. However, if once this procedure is approved a substantial amount of HIV transmissions 
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from organ recipient to others are reported (i.e. far more than anticipated) the ethical analysis could 
change, as in this case it would be less clear that the benefits of this type of transplant outweigh 
the harms. 
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5.0 Considerations of Patient Consent for HIV+ to HIV- Organ Transplantation 
The ability of a patient to consent to a medical procedure is an important concern in any 
medical circumstance and is related to the respect for autonomy principle referenced earlier. When 
a procedure with unknown benefits and harms is considered, patient consent deserves greater 
attention and care than in more ordinary circumstances. Under the HOPE Act, this greater attention 
manifests in the form of a requirement for a HOPE independent recipient advocate (HIRA)9 
(Bollinger et al., 2019). Under HOPE guidelines this advocate must: 
 “i) promote and protect the interests of the HIV-positive 
recipient (including with respect to having access to a suitable HIV-
negative organ if it becomes available)10 and take steps to ensure 
that the HIV-positive recipient’s decision is informed and free from 
coercion; ii) review whether the potential HIV-positive recipient has 
received information regarding the results of SOT [Solid Organ 
Transplantation] in general and transplantation in HIV-positive 
recipients in particular and the unknown risks associated with HIV-
positive transplant; and iii) demonstrate knowledge of HIV infection 
and transplantation” (National Institutes of Health, n.d.). 
 
According to HIRAs themselves, their main responsibilities are “to ensure potential 
participants understand the risks and benefits of receiving and HIV-infected organ and to confirm 
that their decision to participate in the HOPE transplant research study [is] voluntary” (Bollinger 
et al., 2019). These two considerations only apply to potential recipients who wish to participate 
in HOPE Act research—i.e. by being willing to accept an HIV+ organ—and as such HIRA-type 
advocates are not necessary for the majority of potential organ recipients.  
 
9 Independent advocates are not a usual part of transplant procedures (Bollinger et al., 2019) 
10 i.e. choosing to participate in HOPE Act research and have the possibility of receiving HIV+ organs does not mean 
that a potential recipient has to forfeit their position on the waitlist for HIV- organs 
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However, there are additional arguments to suggest that requiring independent advocates 
for HOPE Act related participation may also be unnecessary and potentially harmful. There is the 
concern that requiring interaction with an independent advocate may “inadvertently increase 
participants’ fear in the research by implying that the study’s risks are so great as to warrant 
confirmation of their decision to participate in addition to the usual consent processes that are in 
place” (Bollinger et al., 2019). This is particularly notable given that “most high-risk research 
studies do not require independent advocates for potential study participants” (Bollinger et al., 
2019). As such “the HIRA requirement may signal that HIV D+ to HIV R+ transplants warrant 
special protections that could inadvertently be associated with HIV-related stigma,” rather than 
reflect an accurate depiction of the risks of the procedure (Bollinger et al., 2019). Because 
independent advocates are a limited resource in healthcare it is important to constantly evaluate 
whether the advocate is necessary for the given context or if the resources would be better used in 
other circumstances (Bollinger et al., 2019). 
 A scheme similar to the HIRA system was used in the 2017 South Africa case, where 
Etheredge et al. wrote that a vital part of the consent process for the parents in this case was the 
independent donor advocate (IDA)11 (Etheredge et al., 2019). Etheredge et al. write that they “were 
acutely aware of entering unknown territory and went to great lengths to ensure appropriate and 
detailed communication. [They] emphasized that [they] were unsure whether the child would 
contract HIV. [They] also took care to ensure that both parents had the capacity and social support 
to care for an HIV-positive child in the future” (Etheredge et al., 2019). They note that the IDA 
played a crucial role in this regard, meeting with the parents several times before the procedure 
 
11 Donor, not recipient, because in this case the mother was donating part of her liver to her very young child and as 
such was consenting on her behalf (along with the father of the child) 
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and functioning as an informal representative for the parents post-transplant (Etheredge et al., 
2019). Considering how unusual this procedure was and the myriad of risks involved the use of an 
advocate in this case seems justified despite the extra amount resources required. It seems 
reasonable to propose that an independent recipient advocate should also be a part of the process 
for HIV+ to HIV- organ transplantation in the United States as well—were this policy to be 
enacted—given that the risks of such a procedure would be similarly unknown as they were in 
South Africa four years ago. Furthermore, the ability to accept an HIV- organ should a suitable 
one become available to the potential recipient should continue to be the case and should be 
emphasized as part of the research protocol. As more information on the expected harms and 
benefits of the procedure become available through research it would be possible to reevaluate 
whether the independent advocate was still necessary or if the resources could be diverted 
elsewhere.  
5.1 Rights of Donors and Other Considerations of Fairness 
Up until now, autonomy has been discussed only in the context of the potential organ 
recipient, but the consideration is pertinent to the potential donor as well. Up until recently, people 
living with HIV in the United States did not have the ability to donate their organs—either through 
living donation or after death, but “[w]ith the passage of the HOPE Act, persons living with HIV 
now have the opportunity, indeed the right, to authorize deceased donation or become living 
donors under an IRB-approved protocol” (Durand et al., 2016). The word ‘right’ here is important, 
suggesting that the interests of the person living with HIV who wants to donate their organs have 
special protection that could only be considered void with the introduction of valid reasoning. 
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Otherwise, because of considerations of fairness, the interests of HIV+ potential donors should be 
treated with the same respect given to HIV- potential donors.  
Indeed, there are several major interests to consider. Respect for autonomy persists even 
after death; “[j]ust like there is a duty to respect the will of the individual for disposition of assets, 
so we must respect his or her wishes about what will happen with his or her body” (Veatch, 2000, 
p. 146). If that wish includes a desire to donate one’s organs, this desire should be honored unless 
there exists a compelling reason not to do so. Years before the passage of the HOPE Act, it seemed 
that the compelling reason in the case of people living with HIV was obvious—HIV was an 
extremely deadly disease that significantly reduced quality of life. Asking a potential organ 
recipient to consent to the risks of an operation under the pretense of saving their life only to have 
the recipient gain an organ that would lead to their imminent death makes no sense, and as such, 
it was acceptable to disregard the interest an HIV+ person might have in donating their organs.  
But, as HIV treatment improved, the restriction on allowing people living with HIV to donate their 
organs begins to seem more arbitrary than it had in the past. This was particularly true in cases of 
living organ donation, as the potential donors in these cases often had a connection to the potential 
recipients and wanted to ensure their welfare. Etheredge et al. explain that this was part of the 
reason why they felt it was ethically justified to perform the HIV+ to HIV- transplant in 2017: 
“We have had a number of HIV-positive parents in our 
setting express a desire to be living liver donors for their critically 
ill children. Declining these parents as living donors has become 
increasingly unjustifiable given the very small deceased donor pool 
in [South Africa]; and because many of these parents are virally 
suppressed and would otherwise fulfil our eligibility criteria as 
living donors” (Etheredge et al., 2019) 
 
These parents had an interest in protecting their children and—with new treatments for 
HIV—it seemed arbitrary that they were not allowed to act as living donors. As such, denying 
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these parents the right to donate their organs to their children seems ethically indefensible under 
considerations of fairness, in addition to considerations of beneficence and nonmaleficence that 
have been previously shown to apply to the potential organ recipient in these cases. 
While arguably the major interests of potential donors are the ones already discussed, there 
are a few other potential interests that should be given attention. There are particular benefits of 
organ donation related to people living with HIV, which “include reduced stigma, support of 
community through helping [people living with HIV] awaiting transplant, and belief that the 
HOPE Act creates a more equitable opportunity for transplantation for [people living with HIV]” 
(Nguyen et al., 2018). Expanding transplant guidelines to include HIV+ to HIV- donation could 
further reduce stigma and expand community. 
Allowing for HIV+ to HIV- transplantation could also create an even more equitable 
transplant system for everyone, HIV+ and HIV- alike. Currently, HIV+ potential recipients are 
eligible to receive both HIV+ and HIV- donor organs, whereas HIV- potential recipients are only 
eligible to receive HIV- donor organs. Considering that treatment for HIV has improved to the 
point where it is possible to live a very good life with the virus it seems unfair that HIV- potential 
recipients are excluded from a pool of organs that they could potentially benefit from receiving—
solely because they themselves are not infected with the virus. Allowing HIV+ to HIV- 
transplantation would serve to mitigate this unfair standard.  
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6.0 Allocation Structure Incorporating HIV+ to HIV- Donation 
Making HIV+ to HIV- transplantation permissible does not mean that HIV status has to be 
removed as a consideration in allocation structure. Indeed, there are three main approaches to 
incorporating the new policy into the existing system—1. HIV status of potential recipient has no 
impact on allocation, 2. HIV status has some impact i.e. HIV+ potential recipients have access to 
HIV+ organs before HIV- recipients at the same classification, 3. HIV- potential recipients only 
have access to HIV+ organs once all HIV+ potential recipients have been offered the organs. An 
example schematic of these three structures along with the existing structure is offered in the table 
below—using the allocation of livers as an illustration.  Unlike in the previous section however, 
the following schemes should be understood for how HIV+ organs are to be allocated—not organs 
in general.   
Table 5: Allocation of HIV+ Livers Existing Structure 
Classification Geographic region Criteria 
1 medium Status 1A, HIV+ 
2 medium Status 1B, HIV+ 
3 small MELD/PELD of 40, HIV+ 
4 medium MELD/PELD of 40, HIV+ 
5 small MELD/PELD of 39, HIV+ 
6 medium MELD/PELD of 39, HIV+ 
… … … 
13 small MELD/PELD of 35, HIV+ 
14 medium MELD/PELD of 35, HIV+ 
15 small MELD/PELD > 15, HIV+ 
16 medium MELD/PELD > 15, HIV+ 
17 nation Status 1A, HIV+ 
18 nation Status 1B, HIV+ 




Table 6: Allocation of HIV+ Livers Proposed Structure 1 
Classification Geographic region Criteria 
1 medium Status 1A, HIV+ or HIV- 
2 medium Status 1B, HIV+ or HIV- 
3 small MELD/PELD of 40, HIV+ or 
HIV- 
4 medium MELD/PELD of 40, HIV+ or 
HIV- 
5 small MELD/PELD of 39, HIV+ or 
HIV- 
6 medium MELD/PELD of 39, HIV+ or 
HIV- 
… … … 
13 small MELD/PELD of 35, HIV+ or 
HIV- 
14 medium MELD/PELD of 35, HIV+ or 
HIV- 
15 small MELD/PELD > 15, HIV+ or 
HIV- 
16 medium MELD/PELD > 15, HIV+ or 
HIV- 
17 nation Status 1A, HIV+ or HIV- 
18 nation Status 1B, HIV+ or HIV- 












Table 7: Allocation of HIV+ Livers Proposed Structure 2 
Classification Geographic region Criteria 
1 medium Status 1A, HIV+ 
2 medium Status 1A, HIV- 
3 medium Status 1B, HIV+ 
4 medium Status 1B, HIV- 
5 small MELD/PELD of 40, HIV+ 
6 small MELD/PELD of 40, HIV- 
7 medium MELD/PELD of 40, HIV+ 
8 medium MELD/PELD of 40, HIV- 
9 small MELD/PELD of 39, HIV+ 
10 small MELD/PELD of 39, HIV- 
11 medium MELD/PELD of 39, HIV+ 
12 medium MELD/PELD of 39, HIV- 
… … … 
26 small MELD/PELD of 35, HIV+ 
27 small MELD/PELD of 35, HIV- 
28 medium MELD/PELD of 35, HIV+ 
29 medium MELD/PELD of 35, HIV- 
30 small MELD/PELD > 15, HIV+ 
31 small MELD/PELD > 15, HIV- 
32 medium MELD/PELD > 15, HIV+ 
33 medium MELD/PELD > 15, HIV- 
34 nation Status 1A, HIV+ 
35 nation Status 1A, HIV- 
36 nation Status 1B, HIV+ 
37 nation Status 1B, HIV- 










Table 8: Allocation of HIV+ Livers Proposed Structure 3 
Classification Geographic region Criteria 
1 medium Status 1A, HIV+ 
2 medium Status 1B, HIV+ 
3 small MELD/PELD of 40, HIV+ 
4 medium MELD/PELD of 40, HIV+ 
5 small MELD/PELD of 39, HIV+ 
6 medium MELD/PELD of 39, HIV+ 
… … … 
13 small MELD/PELD of 35, HIV+ 
14 medium MELD/PELD of 35, HIV+ 
15 small MELD/PELD > 15, HIV+ 
16 medium MELD/PELD > 15, HIV+ 
17 nation Status 1A, HIV+ 
18 nation Status 1B, HIV+ 
… … … 
52 nation Any MELD/PELD in need of 
other method of hepatic 
support, and blood type 
compatible with the donor 
53 medium Status 1A, HIV- 
54 medium Status 1B, HIV- 
55 small MELD/PELD of 40, HIV- 
56 medium MELD/PELD of 40, HIV- 
57 small MELD/PELD of 39, HIV- 
58 medium MELD/PELD of 39, HIV- 
… … … 
65 small MELD/PELD of 35, HIV- 
66 medium MELD/PELD of 35, HIV- 
67 small MELD/PELD > 15, HIV- 
68 medium MELD/PELD > 15, HIV- 
69 nation Status 1A, HIV- 
70 nation Status 1B, HIV- 
… … … 
 
Each of these schemes has merit but Structure 2 seems to do the best at balancing our 
existing knowledge with considerations of fairness. Structure 1, by not taking HIV status into 
account, ignores the fact that the US has more experience with HIV+ to HIV+ transplantation than 
with HIV+ to HIV- and that as such the risks are better known and understood for this already-
established practice. Structure 3 on the other hand goes too far in prioritizing HIV+ potential 
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recipients to the extent where a HIV+ person who is not in desperate need of an organ could obtain 
one before a HIV- person who does desperately need it. Structure 2 recognizes that HIV+ to HIV+ 
transplantation might be slightly preferable to HIV+ to HIV-, but does not let this consideration 
get in the way of prioritizing lives and life-years saved. 
6.1 Special Considerations for HIV+ to HIV- Living Donation 
As previously discussed in the section on donor’s rights living donation often involves a 
relationship between the donor and the recipient that is not present with deceased donor 
transplants. Because of this, the donor in this case is likely donating an organ (or part of an organ) 
that otherwise would not be donated—because their special relationship to the recipient is what is 
motivating them to donate the organ. Thus, allowing HIV+ to HIV- living donation has a great 
potential to increase the total number of organs available for transplant because the organ from the 
living donor is only added to that potential pool of donor organs because of the donor’s relationship 
to the recipient. This increase in the total number of available organs is probably even more certain 
with allowing HIV+ to HIV- living donation than HIV+ to HIV- deceased donation because with 
living donation one can be certain that an organ that otherwise would not have been available has 
been transplanted—whereas while that is certainly possible with HIV+ to HIV- donation it is not 
a guarantee.  
Another consideration pertinent to HIV+ to HIV- living donation is the fact that in general 
living donation transplantations have better outcomes than deceased-donor transplantation—for 
example, the graft half-life for a living donor kidney is more than a year longer than a deceased 
donor kidney with a 0-20% KDPI, and the difference is even greater for kidneys with higher KDPIs 
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(“Kidney Donor,” n.d.). If the choice for the recipient is between a HIV+ organ from a living 
donor and a HIV- organ from a deceased donor, the benefits from receiving an organ from a living 
donor might be enough to outweigh the potential harms that could come from receiving an organ 
from a deceased donor.  
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7.0 What We Still Don’t Know and How this Information Could Change our Ethical 
Analysis 
There have been several times in this discussion where an important statistic is simply not 
known because intentional HIV+ to HIV- organ transplant is such a new idea. If HIV+ to HIV- 
transplantation were to be implemented these would be the rates to pay the closest attention to in 
research.  
Firstly, it is technically unknown if under this new guideline more organs will actually be 
used or if instead just the people who receive the organs will change. I previously put forth 
arguments suggesting why it is likely that more organs will be transplanted, but I admit that it is 
still possible that in practice this new procedure does not increase the number of transplants or the 
number of lives saved. The arguments in favor of the procedure in terms of beneficence 
considerations would then be weaker because the possible benefits would be less likely to 
outweigh the harms of transplanting an HIV+ organ into an HIV- person. A second important 
consideration is rates of compliance with post-transplant treatment. We often talk about 
compliance/adherence to post-transplant medication as an issue in organ donation—with the idea 
that organs should only be given to those who will adhere to the treatment necessary to sustain the 
graft (and therefore, not “waste” the organ). But in cases where recipients contract HIV as a result 
of the transplant, not adhering to treatment could have the additional consequence of spreading 
HIV to those who if the transplant had not been done, would not have been infected. The harms 
that such transmissions from the recipient to others would cause would have to be outweighed by 
the benefits of the transplant—i.e. in saving more lives and improving quality of life for the 
recipient. Lastly, as with any new procedure, there are ‘unknown unknowns’ which could manifest 
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and greatly change the cost/benefit ratio. Importantly however, these unknowns are not reasons to 
prohibit HIV+ to HIV- transplantation a priori—rather they are important factors to research 
should the procedure be enacted. As more information becomes available and these arguments turn 
from speculation to observed phenomenon the true benefits and risks of HIV+ to HIV- 
transplantation will be known and a more informed ethical analysis can occur. 
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8.0 Moving Forward: Potential Benefits of HIV+ to HIV- Organ Transplantation to Organ 
Recipients not at Immediate Risk of Death 
Up until now I have mainly been arguing for the allowance of HIV+ to HIV- transplantation 
for potential organ recipients who would likely not receive another organ offer—and as such have 
their lives dependent on whether or not they would be allowed to accept an HIV+ organ offered to 
them. In this section however, I would like to discuss other HIV- potential recipients who might 
benefit from HIV+ transplantation. In the case of kidney failure in particular the need for an 
immediate transplant isn’t as great because a person can live for several years on dialysis (“What 
Is dialysis?,” 2015). Because of the ability to live for long periods of time on dialysis the potential 
organ recipient can be fairly confident that should they reject a kidney offered to them it will not 
be the last one they are offered. The question then for many people waiting for a kidney transplant 
is whether to accept any kidney offered to them or wait for a kidney deemed “better” in some 
way—for example a kidney with a lower KDPI or from a younger donor. It seems that in most 
cases—whether the kidney is “worse” because it comes from an older donor, has a higher KDPI, 
or has a greater risk of HIV or HCV infection—the potential organ recipient is still better off 
accepting the “worse” kidney than waiting for another (Bae et al., 2019; Bowring et al., 2018; 
Ruck & Segev, 2018). It then seems logical to suppose that there might be cases where an HIV- 
potential recipient would be better off accepting an HIV+ kidney that becomes available to them 
instead of waiting for an HIV- kidney. Because HIV+ to HIV- transplantation is currently not well 
understood when the procedure is first legalized it would be sensible to confine it to those who 
will likely die without an organ—any organ. Additionally, HIV- people who have the ability to 
wait for an HIV- organ would likely be inclined to do so given how unknown the risks of receiving 
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an HIV+ organ. But, if as more information becomes available the procedure consistently results 
in good outcomes with few downsides then expanding access to those who are not at immediate 
risk of death but could still benefit from the procedure would be prudent.  
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9.0 Conclusion 
No one policy is going to solve the organ shortage in the United States. But, in a country 
where so many are waiting for an organ with so few available even a small change in policy has 
the potential to save lives. Because of the advances in HIV treatment and prevention HIV+ to HIV- 
organ transplantation has become a policy worth considering in an effort to achieve the combined 
goals of reducing the organ shortage and saving lives. There are many unknowns associated with 
this procedure but none of them warrant prohibiting the procedure in of itself given the likely 
benefits that are also associated with it. Research on the outcomes of the procedure once it is 
implemented will help eliminate these unknowns and determine whether it is prudent to continue 
such procedures given current medical technology. Thus, legalizing HIV+ to HIV- transplantation 
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